deficiency

Hematopoietic stem cell transplantation for childhood immunological diseases
Allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of childhood immunological deficiencies has been successfully applied since 1968. [1] [2] [3] Among the primary immune deficiency diseases that have shown good clinical responses are severe combined immune deficiency (SCID), Wiskott-Aldrich syndrome, X-linked hyper-IgM (CD154 {CD40 ligand} deficiency), chronic granulomatous disease (CGD), leukocyte adhesion defect (CD18 deficiency), hemophagocytic lymphohistiocytosis and so on. Because these diseases are due to defects manifested in lymphoid or myeloid cells, which are, in turn, derived from hematopoietic stem cells (HSCs), the provision of a source of normal HSC allows correction of the underlying blood cell production or functional deficiencies. In general, it is possible to achieve high rates of immune reconstitution (490%) with good survival and quality of life, performing a transplant from an HLA-matched sibling donor, unless there are active opportunistic infections or their consequent complications. For SCID patients, it is possible to infuse HLA-matched sibling donor marrow without 'conditioning' and to restore T-cell function in most patients. Most other childhood immunological diseases require full or partial marrow conditioning both to 'make space' to get enough donor cells engrafted to correct the immune deficiency and to prevent allo-reactivity and graft rejection. In any allogeneic HSCT, GVHD is a significant problem and may become a chronic condition.
When an HLA-matched sibling donor is not available, HSC from bone marrow, PBSC or neonatal cord blood obtained from haplo-identical donors (for example, parent) or matched unrelated donors (MUD) may be used. Although lower than the success rates with sibling donors, MUD HSCT for childhood immunological deficiencies generally have overall better outcomes than haploidentical HSCT (B30-70%). [2] [3] [4] [5] The lower success rates may reflect increased risks of graft rejection and/or GVHD, as well as effects of immune suppression or T-cell depletion used to prevent GVHD, causing slower immune reconstitution with increased risks from infections.
Gene therapy for the childhood immunological diseases
The basic hypothesis driving efforts to develop gene therapy for childhood immunological diseases is that gene therapy using autologous HSC that are corrected with the normal gene will have a beneficial effect on blood cell production or function, without the immunologic complications of allogeneic HSCT. As reported at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in June 2007, 79 subjects with primary immunodeficiency disease (PID) have been enrolled in 21 gene therapy studies since 1990 (Table 1) . Hemoglobinopathies, lysosomal and metabolic disorders and defects of hematopoietic stem and progenitor cells should also be ameliorated by gene correction of autologous HSC.
Clinical applications of gene therapy using hematopoietic stem cells
Initial considerations for the use of gene therapy centered on hemoglobinopathies, after b-globin was the first human gene cDNA to be cloned. However, by the mid-1980s, the field's focus turned toward applications for immune deficiencies, especially SCID. On the basis of the clinical responses of SCID patients to sibling transplants without ablation, it was postulated that normal lymphoid progenitor cells would have a selective survival advantage compared to the congenitally deficient endogenous lymphoid cells. In that setting, even a low level of genecorrected HSC could lead to clinically beneficial immune reconstitution. Adenosine deaminase (ADA) was the first gene associated with a form of human SCID to be identified and cloned. Thus, initial trials of gene therapy for childhood immunological diseases focused on ADA-deficient SCID, which accounts for approximately 15-20% of human SCID.
Gene transfer to HSC
Hematopoietic stem cells are unique in that they can be removed from the body, modified ex vivo and retransplanted with preservation of their function ( Figure 1 ). For gene therapy done by adding a normal gene to HSC, vectors that integrate the gene into the cell's chromosomes, such as retroviral and lentiviral vectors, are required. Vectors derived from adenovirus, adeno-associated virus and herpes viruses do not integrate and would be lost once the HSC begin to proliferate.
Studies of gene transfer to HSC have been ongoing since the mid-1980s. Retroviral vectors derived from murine retroviruses can efficiently and permanently introduce genes into murine HSC, leading to the presence and expression of the transgene in the majority of all blood and immune cells produced for the life of the recipient and even in secondary recipients of the marrow upon serial Figure 1 Gene therapy for childhood immunological diseases. Autologous hematopoietic stem cells (HSCs) are harvested from the patient's bone marrow, cord blood or peripheral blood. In the laboratory, CD34 þ stem/progenitor cells are isolated and engineered by gene addition or gene correction. The cells are formulated for clinical administration and tested to certify that they meet release criteria. During this time, the subject may receive cytoreductive chemotherapy to 'make space' for the manipulated cells, which are then reinfused intravenously. After the gene therapy procedure, patients are followed to assess safety, the clinical outcome of the intervention, the frequency of blood cells containing and expressing the modified gene and the vector-integration site patterns.
transplantation. Transduction of HSC from larger mammals (dogs, monkeys and humans) by murine retroviral vectors has proven to be significantly less effective. This inability to efficiently modify human HSC has been the major rate-limiting step in the development of effective gene therapy for blood cell diseases. The mechanisms underlying the poorer transduction of HSC of human compared to murine origin are not fully known. A higher fraction of human HSC than murine (defined by immunophenotype) are quiescent (G o ) and thus not directly susceptible to transduction by retroviral vectors. Stimulating the proliferation of human HSCs/progenitor cells using recombinant hematopoietic cytokines or growth factors (for example, c-kit ligand, flt-3 ligand and others) increases gene transduction by retroviral vectors. 6 However, the in vitro manipulation of HSC needed for transduction by murine retroviral vectors (typically 3-4 days of ex vivo culture) causes loss of stem cell properties as they become more differentiated progenitor cells, which diminishes their longevity, generative capacity and pluripotency. 7 Early trials (1990-1996) of gene therapy for ADA-deficient SCID Six trials of gene therapy for ADA-deficient SCID were performed in the early 1990s. All used retroviral vectors to transfer a normal human ADA cDNA. Studies targeted peripheral blood T cells or CD34 þ hematopoietic progenitor cells from bone marrow or cord blood in ADAdeficient SCID patients. [8] [9] [10] [11] [12] In retrospect, the following conclusions can be made about these early clinical trials of ADA gene therapy. The methods used to culture and stimulate the T cells and CD34 þ cells for ex vivo gene transfer are now considered to be suboptimal. T cells were activated with a monoclonal antibody to CD3 and high concentrations of IL-2 and the CD34 þ cells were transduced using cytokines that do not act on the earliest pluripotent HSC (for example, IL-3/IL-6) in 'bare' flasks, which poorly support HSC maintenance. No marrow cytoreductive conditioning was used to 'make space', and thereby increase the fraction of engrafted HSC and their proportionate contributions to lymphohematopoiesis. Additionally, all of the subjects continued to receive enzyme replacement therapy with a pharmacological ADA enzyme-polyethylene glycol conjugate (PEG-ADA-Adagen) after undergoing gene therapy. It was subsequently shown in several contexts that ADA enzyme replacement therapy blunts the selective advantage of ADA-replete T cells in ADA-deficient SCID patients. 13, 14 There were no serious adverse events, but there were also no significant clinical benefits achieved. The transduced, reinfused T cells have persisted for many years, but the breadth of the immune repertoire diversity has been uncertain. There was low-level gene transfer and engraftment of HSC. Despite some claims made at the time that the gene therapy had improved the children's immunological function, their survival and immune function have been comparable to patients on PEG-ADA therapy only. 15 Improved methods for gene transfer to HSC led to second-generation clinical trials Subsequently, there were successive incremental improvements in the clinically applicable methods to increase the level of gene-containing HSC that are transduced and engrafted, contributing to mature blood cell pools. Murine retroviral vectors were simplified to contain only the cDNA of interest under control of the long terminal repeat (LTR), and these could be produced to high titers and strongly expressed the transgene. Improved vector production and processing methods, and the use of alternative envelope proteins (GALV, VSV-G and RD114) also increased gene transfer levels. Most significantly, new reagents were developed that support better the cultured CD34 þ cells during ex vivo transduction and lead to greater levels of gene transfer and engraftment. Cytokines that stimulate the activation of primitive hematopoietic stem and progenitor cells (for example, c-kit ligand, flt-3 ligand and thrombopoietin) and extracellular protein matrix that colocalizes cells and vectors together (recombinant fibronectin), both act to support HSC survival and transduction, and thereby increase the recovery of gene-modified stem cells for reinfusion. 16, 17 The use of these improved methods was shown to lead to incremental increases in the levels of HSC (1-10%) that are transduced and engraft long term in critical non-human primate HSC transplant studies following marrow-ablative dosages of total-body irradiation (for example, 1200 cGy). 18 On the basis of these advances, a second generation of clinical trials for SCID were initiated in late 1990s.
Gene therapy for ADA-deficient SCID
Physicians/scientists at the Hospital San Raffaele in Milan, Italy treated ADA-deficient SCID infants with retroviral gene transfer to autologous marrow CD34 þ cells. 19 This was the first clinical trial of gene therapy to administer chemotherapeutic agents to 'make space' in the bone marrow to increase the contribution to blood cell pools by the reinfused HSC. Following bone marrow harvest, during the ex vivo transduction period, the subjects received busulfan, a potent agent for elimination of marrow stem cells, at a dosage (4 mg/kg) that was approximately 15-25% of the dosage used in pediatric patients in regimens with the intent of complete marrow cytoablation (600-640 mg/m 2 ). The patients also were not given PEG-ADA enzyme replacement therapy, to allow the maximum selective advantage of the gene-corrected lymphoid cells to be manifest.
These children appreciated significant and beneficial immune reconstitution. Over the first 6-9 months, immune function was restored with the development of antigenspecific T cell responses and evidence of antibody production. Seventy-five to hundred percent of T, B and NK cells contained the transferred ADA gene. Up to 10% of the myeloid cells contained the transferred ADA gene; thus, the busulfan achieved the intended effect, as this level of myeloid marking, in the absence of an intrinsic selective survival advantage, had not been observed in several prior studies with retroviral vectors that avoided chemotherapy. The successful results in the first two reported patients have now been extended with restoration of protective immunity in at least 12 patients in Milan, 2 in London (using melphalan instead of busulfan) and one in a study being conducted at Childrens Hospital Los Angeles and the National Institutes of Health. 19, 20 Gene therapy for X-linked SCID
The single most common genetic cause of human SCID is the X-linked mutation of the common cytokine receptor (gC) gene, needed for the development and function of lymphocytes. A clinical trial from Hopital Necker-Enfants Malade in Paris performed retroviral-mediated transfer of a normal human gC cDNA into CD34 þ cells from bone marrow of 10 infants with X-linked SCID (XSCID). 21 The transduced CD34 þ cells were given without any prior cytoreduction. There were no acute adverse events noted in the initial period in all 10 subjects. The gC gene was present and expressed in T, NK and B lymphocytes. Over 2-5 months after gene therapy, 9 of the 10 infants developed normal numbers of T and NK cells, with good immune function (one had a confounding pre-existing infection). 22 B-cell numbers remained low, although protective levels of antibodies persisted, off IVIg. They were in good health over the first 1-2 years, without opportunistic infections and were growing and developing without protective isolation. Four XSCID children were treated at Great Ormond Street Hospital, London using a similar approach with retroviral vectors into autologous HSC and also achieved good clinical outcomes and immune reconstitution. 23 Tragically, after these promising results were reported, four subjects developed a T cell leukemia-like complication, with escalating white blood cell counts, 2.5-5 years after the gene therapy procedure. 24 Evidence implicates insertional oncogenesis from the retroviral vectors as the cause. In the cases analyzed to date, the leukemia cells had intact, unaltered vector at low copy numbers (1-4/cell) with individual clonal integration patterns in each patient. In the first three patients' leukemia cells, the vector was integrated on chr11p13, near the first exon of the LMO-2 gene. LMO-2 encodes a protein involved in stem cell growth, and it is normally not expressed in T cells. It is inappropriately activated by translocation in some spontaneous cases of T cell leukemia, implicating it as a protooncogene.
Retroviral vectors may cause 'insertional oncogenesis' by 'turning-on' cellular proto-oncogenes adjacent to where they integrate into the target cell chromosomes. The strong genetic elements in murine retroviral vectors that are used to drive expression of the therapeutic gene (especially their LTR) may also transactivate the expression of nearby cellular genes. Recent studies indicate that retroviral vectors integrate preferentially into the 5 0 end of genes, which would place them close to the promoters of the cellular gene that they may then deregulate. 25 It is not thought that the vector integrated preferentially adjacent to the LMO-2 gene; rather, retroviruses integrate (semi)-randomly at different sites in the chromosomes of each cell they transduce. Rare events of integration of retroviral vectors near a cellular proto-oncogene with transactivation may cause clonal expansion, with later secondary changes leading to cellular transformation.
A series of papers reported analyses of the vectorintegration sites in cells from the subjects of the clinical trials of gene therapy for ADA-deficient SCID and XSCID. [26] [27] [28] [29] All three studies observed that the vectors had a greater than random frequency of integrating near the gene promoters at the 5 0 ends of genes. There was a bias for the vectors to be integrated adjacent to genes that are expressed in CD34 þ cells. The initial patterns of vector integration in the cells prior to reinfusion became skewed in vivo, with increasing percentages of cells containing vectors integrated near promoters in cells recovered from the patients months and years after treatment. Insertional activation of cellular genes that increase cell survival or decrease cell death may promote selective outgrowth of cells with vectors integrated near those genes. These analyses did not reveal predictive patterns of integration sites that distinguished the patients who went on to develop T lymphoproliferation from those who did not.
It remains uncertain why this complication of T lymphoproliferation occurred in a subset of the XSCID patients, but not in any of the ADA-deficient SCID patients. There is some evidence that LMO-2 and gC may cooperate in causing T cell transformation in mice. 30 Different genes to be used for gene therapy of childhood immunological diseases may have differing intrinsic risks for being involved in cellular transformation. It may be speculated that genes encoding signal transduction proteins (gC, JAK3, btk, Zap70 and CD40 ligand) would have greater potentials for activating cellular proliferation than genes encoding housekeeping enzymes or structural proteins (ADA, phox proteins, CD18 and perforin).
At present, it is not clear whether allogeneic HSCT or autologous gene therapy/HSCT provides the greater ratio of benefits to risks ( Table 2 ). The survival for SCID patients transplanted using haplo-identical or unrelated HSCT (n4300) is in the range of 50-70%, with restored T cell immunity in most, but as high as 50% failure to produce protective antibodies. [2] [3] [4] [5] These patients have some risks of severe or chronic GVHD and a small risk for post transplant lymphoproliferative disease. For SCID patients undergoing gene therapy using autologous, gene corrected HSCT in the second generation trials (no30), the mediumterm survival (1-5 years) with immune restoration is in the range of 70% for XSCID and 100% for ADA-deficient SCID. The occurrence of T cell lymphoproliferation in more than one quarter of the XSCID children presents a new and severe risk, which may be specific to the disease and its relevant gene. It is too early to know whether the long-term outcomes with gene therapy for SCID will exceed, equal or be worse than those with allogeneic BMT for SCID.
Gene therapy for chronic granulomatous disease
More recently, a clinical trial for the neutrophil disorder CGD has been reported to yield significant clinical benefits. 31 Two young men in their twenties with X-linked CGD and severe chronic infections not responsive to intensive medical therapy were enrolled. PBSCs were mobilized with G-CSF, CD34 þ cells were isolated and then transduced using a retroviral vector carrying a normal human gp91phox cDNA controlled by a retroviral LTR that mediates high-level expression in myeloid cells. They received a higher dosage of busulfan (8 mg/kg) than in the ADA trial, the equivalent of B50% of a fully ablative dosage, followed by CD34 þ cell reinfusion.
There was rapid recovery of the chemotherapy-induced neutropenia, with production of gene-corrected, oxidase ( þ ) neutrophils. Importantly, there were clinically beneficial responses to the chronic infections. The frequency of gene-containing neutrophils in peripheral blood was 20% in the first few months and then increased to 80% at approximately 4-6 months. Unexpectedly, most of the cells had the vector integrated near 1 of 3 genes that have been implicated in the proliferation of myeloid cells, suggesting that transactivation of these genes by the vector led to oligoclonal proliferation. One of these patients remains in good health, but the other has died with evidence suggesting loss of expression of the gp91 phox gene. A third subject was subsequently treated in this study with an excellent clinical response to a deep-seated fungal infection. One CGD patient was treated recently at the National Institutes of Health (Bethesda, MD, USA).
Realizing the benefits of gene therapy with lower risk
It may be anticipated that the next incremental improvement in gene therapy using HSC will be the use of lentiviral vectors, derived from HIV-1. 32 Lentiviral vectors have an additional advantage over murine retroviral vectors in that they accommodate larger, more complex gene-expression units. Lentiviral vectors have been developed that carry and express relatively complex b-globin gene cassettes, and these will likely be assessed in clinical trials for betathalassemia and sickle cell disease in the next several years. 33 Lentiviral vectors have not proven superior to g-retroviral vectors for gene transduction of long-term engrafting HSC in non-human primate HSC transplant models. There are species-specific restriction of HIV-1 by non-human primate cells (by TRIM5a and possibly other mechanisms) that pose an artificial barrier that would not be operant when targeting human HSC. A recent paper using an SIVbased lentiviral vector in fully ablated rhesus macaques did yield levels of gene marking similar to the best seen with g-retroviral vectors. 34 Lentiviral vectors have not yet been assessed in clinical trials using HSC. Lentiviral vectors have entered the clinic in a trial with HIV-1-infected subjects that targeted peripheral blood T lymphocytes. 35 Clinical trials using lentiviral vectors to transduce HSC for blood cell diseases are in development for hemoglobinopathies, X-linked adrenoleukodystrophy, metachromatic leukodystrophy, Wiskott-Aldrich syndrome and Fanconi's anemia.
There is great interest in developing safer vectors that retain the properties of efficient and nontoxic gene delivery to primary cells, but with lower risks of genotoxicity. Approaches being studied include the use of weaker enhancers/promoters in vectors to minimize proto-oncogene transactivation, the inclusion of 'insulator' sequences that may block interactions between vector and cellular transcriptional elements, or the inclusion of 'suicide' genes to allow ablation of overproliferative cells. There is some evidence to suggest that these approaches do lead to lower risks, but they are not yet definitive. 36 Vectors derived from the human foamy virus, a nonpathogenic spumavirus, have been developed and shown to mediate efficient and stable gene transduction of human and large mammal HSC. 37 Dogs with canine leukocyte adhesion deficiency have had excellent clinical results from transduction of the marrow HSC using human foamy virus vectors with the canine CD18 cDNA. 38 New (semi)-viral systems have been developed for stable gene delivery (for example, the sleeping beauty transposon and the PhiC31 integrase system), which may have more favorable patterns of integration with lower propensity for integration near proto-oncogenes. 39, 40 However, these plasmid-based systems are currently limited by the difficulty of delivering them to cells with efficiency and without undue cytotoxicity. 41 Gene correction methods seek to repair disease-causing mutation in a patient's own gene, rather than adding a new copy of the relevant gene. Gene correction may have advantages over gene addition in that the therapeutic gene is corrected in its normal location in the chromosomes and so should be expressed in the normal pattern and at normal levels. Gene correction would avoid the problems that may occur from inserting genes semi-randomly throughout the genome, which may lead to transactivation of nearby genes. A recent advance was obtained by Urnov et al. 42 who showed that directing a double-stranded DNA break to be made by engineered zinc-finger nucleases at the intended site for gene correction greatly increases the efficiency of gene correction by homologous recombination to levels that may be clinically applicable.
In summary
At present, gene therapy has been beneficial for patients with XSCID, ADA-deficient SCID and CGD. The principle that partial marrow conditioning increases engraftment has been demonstrated. Clinical trials are being developed in Europe and the United States to treat LAD and Wiskott-Aldrich syndrome and other blood cell disorders. This progress is tempered by the serious complication observed in XSCID patients developing T lymphoproliferative disease. New methods for gene transfer (lentiviral and foamy viral vectors, semi-viral systems and gene correction) may retain or further increase the efficacy and decrease the risks from gene therapy. Ultimately, the relative benefits and risks of autologous gene therapy will be weighed against other available options (for example, allogeneic HSCT) to determine the treatment of choice. If gene therapy using HSC for childhood immunological deficiency disease can truly be made safe and effective, then less severe disorders, such as X-linked agammaglobulinemia and others may also be addressed.
